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Anti-platelet therapy in graft thrombosis: Results of a prospective,
randomized, double-blind study. Hemodialysis (HD) vascular access
thrombosis remains a major cause of morbidity, accounting for 17.4% of
all HD patient hospital admissions in 1986. We initiated this prospec-
tive, randomized, double-blind, placebo-controlled, parallel group
study to examine if dipyridamole and/or aspirin decreased the rate of
thrombosis of expanded polytetrafluoroethylene (ePTFE) grafts in HD
patients. Two patient groups were studied: Type I—with a new ePTFE
graft; and Type II—with thrombectomy and/or revision of a previously
placed ePTFE graft. One hundred and seven patients were followed for
18 months or until the first thrombotic episode. Actuarial analysis of
Type I patients showed cumulative thrombosis rates (mean SEM) of
21 9% on dipyridamole alone, compared with 25 11% on dipyri-
damole and aspirin combination, 42 13% on placebo, and 80 12%
on aspirin alone. The relative risk of thrombosis with dipyridamole was
0.35 (P = 0.02) and that for aspirin was 1.99 (P = 0.18). In Type II
patients, the rate of thrombosis was high in all study drug and placebo
groups (overall 78% thrombosis) and actuarial analysis was not carried
out because of the small number of patients enrolled. We conclude that
dipyridamole is beneficial in patients with new ePTFE grafts and that
aspirin does not improve the risk of thrombosis in ePTFE grafts.
Neither dipyridamole nor aspirin has any beneficial effect in patients
with prior thrombosis of ePTFE grafts.
Complications of the vascular access, particularly stenosis
and thrombosis, continue to remain the Achilles' heel of hemo-
dialysis (HD) therapy and lead to extensive morbidity in HD
patients. In 1986, end-stage renal disease (ESRD) patients had
approximately 30,000 vascular access related hospital admis-
sions (with a median duration of 7 days each) constituting 17.4%
of all hospital stays in this population [11. In addition to its
impact on patient morbidity, the annual cost for placement and
maintenance of vascular access is estimated to be approxi-
mately $500 million [2].
The autologous brachio-cephalic (Brescia-Cimino) fistula re-
mains the access of choice, since its patency and rate of
infection are superior to those made of exogenous material once
early failures are excluded [31. However, polytetrafluroethylene
(PTFE) arteriovenous grafts are used with increasing fre-
quency. In 1990, 83% of vascular accesses placed in Medicare-
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dependent ESRD patients were PTFE grafts [4]. This is attrib-
uted to an increased proportion of elderly patients, female
gender, diabetic patients, and patients with multiple prior
indwelling intravenous catheters or prior failure of autologous
fistulae, all of whom tend to have poor vasculature that pre-
clude the formation of autologous fistulae.
Hemodialysis vascular access thrombosis can occasionally
be attributed to mechanical factors, and at times to a hyperco-
agulable state [5]; however, neointimal hyperplasia and stenosis
at the venous anastomosis appear to be the most common
factors associated with thrombosis [6—8]. Platelet activation has
been proposed to play an important role in the development of
neointimal hyperplasia, and several studies have been per-
formed to assess the efficacy of anti-platelet drugs in the
prolongation of patency of vascular grafts. Anti-platelet therapy
has been reported to decrease thrombosis in external silastic
cannula such as the Scribner shunts used for dialysis vascular
access [9, 10], and data from animal studies have demonstrated
their efficacy in large vessel vascular grafts [11—13]. The com-
bination of aspirin and dipyridamole was also shown to be
effective in human femorodistal PTFE grafts [141. However, to
our knowledge the long-term efficacy of anti-platelet therapy in
the prevention of thrombosis of new or revised PTFE grafts in
chronic HD patients has not been reported.
This prospective, randomized, double-blind, placebo-con-
trolled, parallel group study was undertaken to examine if
dipyridamole (PERSANTINE°) and/or aspirin decreased the
rate of thrombosis of prosthetic arteriovenous expanded PTFE
(ePTFE) grafts in patients on chronic HD.
Methods
Patients
The study was designed to investigate the effectiveness of
anti-platelet therapy in two populations of patients: (a) Type I:
Patients who required a new arteriovenous ePTFE graft for
chronic HD. These included patients who were close to initia-
tion of chronic HD, as well as patients who were on chronic HD
but required placement of a new ePTFE graft at a different site.
(b) Type II: Patients on chronic HD who already had an
arteriovenous ePTFE graft but who developed graft thrombosis
and required a thrombectomy and/or revision by interposition
of a new ePTFE segment.
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Note that once patients participated in the study as either
Type I or Type II, they were not eligible for further participa-
tion, that is, each patient was entered only once. There was no
restriction on participation because of age, gender, diagnosis or
prognosis.
Prior to enrollment, patients underwent a complete history
and physical examination. Baseline laboratory investigations
included a complete blood count, fasting SMA-20 and urinalysis
(if available). Criteria for exclusion from the study were:
uncontrolled hypertension (defined as a sitting diastolic blood
pressure greater than 110mm Hg), history of active peptic ulcer
disease, hemophilia, von Willebrand's disease or other bleeding
disorders, patients with neoplastic disorders and hypersensitiv-
ity to aspirin or dipyridamole.
Treatment protocols
Patients were randomly assigned to one of four drug regi-
mens:
(1) Dipyridamole 75 mg three times a day (tid) with "aspirin"
placebo once a day (qd);
(2) "Dipyridamole" placebo tid with aspirin 325 mg qd;
(3) Dipyridamole 75 mg tablet tid with aspirin 325 mg qd; or
(4) "Dipyridamole" placebo tid with "aspirin" placebo qd.
Placebo drugs looked identical to actual drugs and were
similarly packaged. Neither patient nor investigator could de-
termine the specific treatment protocol assigned to the patient.
Randomization was done using a predetermined schedule.
Aspirin or its matching placebo was taken with meals and
during the initial daily dose of dipyridamole or "dipyridamole"
placebo. Study medications were generally initiated one to two
days prior to insertion of a new ePTFE graft or its thrombec-
tomy, or within one day following the surgical procedure.
Because of this requirement, and because thrombectomies of
pre-existing grafts were generally performed in an outpatient
setting, there were more Type I patients enrolled in the study
than Type II patients.
Concomitant therapy
There was no attempt to change any parameters of dialysis
prescription, including heparin dosage. Aspirin-containing med-
ications, sulfinpyrazone, prostaglandin inhibitor drugs (indo-
methacin, ibuprofen, phenylbutazone, oxyphenylbutazone,
naproxen, fenoprofen, tolmetin, and zomepirac), clofibrate,
coumarins, theophylline, caffeine-containing medications, and
colchicine were not prescribed during the study. Occasional use
of coffee was allowed. None of the patients received erythro-
poietin (EPO) during the study period (1982 to 1988) as the drug
was not available for general use in that time interval.
Follow-up
The primary endpoint of the study was thrombosis of the
ePTFE graft. Thrombosis was detected by the lack of blood
flow by palpation and auscultation or the presence of thrombus
detected during introduction of the dialysis needle into the
graft. Patients were evaluated by an investigator every two
months for 18 months or until graft thrombosis, whichever
occurred earlier. At the conclusion of the observation period
(18 months or at the time of graft thrombosis), physical exam-
ination and laboratory tests were repeated. Adverse reactions
to the drugs were recorded throughout the study. Compliance
was determined by pill count, and by determining the level of
thromboxane B2 in aliquots of platelet-rich plasma (as a marker
of aspirin intake).
Statistics
The primary null hypothesis of the study was that dipyridam-
ole has no effect on graft thrombosis. Thrombosis rates were
determined by both crude and actuarial rates. Crude thrombosis
rates were determined for each arm of the study by calculating
the proportion of patients with thrombosis at the end of the
study period; these rates were then analyzed with Chi-square
test. Although crude rates serve to introduce the results in
simple terms, they fail to account for the time-to-observed
event and for early withdrawals. We therefore used actuarial
analysis for each treatment group as the primary analysis to
determine the proportion of failed grafts as well as differences in
rates of thrombosis between study drugs. In the actuarial
analysis, observations on patients without thrombosis were
considered to be independently censored at the last completed
visit, and are therefore grouped into 60-day intervals corre-
sponding to the planned time between patient visits.
The specific actuarial analysis used for testing the null
hypothesis was the Cox proportional hazards model, with terms
for dipyridamole and aspirin and stratified by type of patient,
that is, Type I or Type II. The initial application of the Cox
model indicated statistically significant treatment-by-type inter-
action, suggesting that Type I patients differed in outcome from
Type II patients. We, therefore, carried out the Cox analysis
separately for Type I patients. Because this analysis was
considered to be a subgroup analysis with repeated testing,
calculated P values for each group of patients were multiplied
by 2 in order to adjust for the repeated testing. There were too
few Type II patients to warrant a separate analysis of their data.
Therefore, the results of the study will emphasize the outcome
of Type I patients.
Results are expressed as mean SEM unless otherwise
indicated. P < 0.05 was considered statistically significant.
Results
Outcome analysis
Patients were enrolled from April 1982 to February 1988.
There were 108 patients (63 females and 45 males) admitted to
the study. The mean age was 54.4 years (range: 19 to 84 years),
the mean weight was 157.2 pounds (range: 70 to 255 pounds),
and the mean height was 65.8 inches (range: 55 to 73 inches).
Seventy-four patients were white, 32 were black, and the
remaining two were hispanic. Demographic and baseline char-
acteristics summarized by treatment type are given in Table 1.
Of the 108 patients entered in the study, one patient (#51)
was excluded because he received a Brescia-Cimino fistula
instead of ePTFE graft after enrollment in the study. Thus,
there were 84 Type I patients and 23 Type II patients enrolled
into the study. Eleven patients did not complete the protocol.
Two of them were lost to follow-up and the remaining were
dropped from the study because of transplantation or patient
refusal to continue. Ninety-six patients were considered to have
completed the protocol (Table 2). For a patient to have com-
pleted the protocol, the patient either completed all visits over
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Table 1. Patient characteristics
Treatment groups
Dipyridamole
Dipyridamole Aspirin + aspirin Placebo Total
Type I patients
Age years
Mean SD 56.6 15.0 56.7 14.5 51.3 17.8 55.3 10.6 54.9 14.8
Gender
Male 6 13 7 10 36
Female 17 7 16 9 49
Race
Black 4 6 6 8 24
White 18 13 17 11 59
Other 1 1 0 0 2
Height inches
Mean SD 65.2 3.4 66.9 4.0 65.9 4.0 66.6 4.6 66.1 4.0
Weight pounds
Mean SD 155.2 37.5 164.1 29.8 158.1 39.8 161.9 42.8 159.6 37.3
Type II patients
Age years
Mean SD 62.2 16.7 43.0 17.5 48.5 22.2 57.0 15.8 52.5 18.7
Gender
Male 1 3 2 3 9
Female 5 3 4 2 14
Race
Black 2 2 2 2 8
White 4 4 4 3 15
Height inches
Mean SD 63.5 2.4 63.6 4.7 64.8 3.5 67.4 2.5 64.7 3.6
Weight pounds
Mean SD 145.5 31.3 130.4 22.3 166.8 43.0 146.8 17.4 148.2 31.7
Table 2. Outcome
Treatment groups
Dipyridamole
Dipyridamole Aspirin + aspirin Placebo Totala
Type I patients
A. Treated 23 20 22 19 84
B. Complete per protocol
1. No thrombosis 14 9 13 12 48
2. Thrombosis 4 (17%) 10 (50%) 5 (23%) 6 (32%) 25 (30%)
C. Incomplete per protocol
1. Lost to follow-up
2.Other"
1 1 0
4 0 4
0
1
2
9
Type II patients
A. Treated 6 6 6 S 23
B. Complete per protocol
1. No thrombosis 1 3 0 1 5
2. Thrombosis 5 (83%) 3 (50%) 6 (100%) 4 (80%) 18 (78%)
a One patient was excluded because he received Cimino fistula instead of ePTFE graft alter enrollment into the study. The study population was
therefore reduced to 107 patients.
b Reasons included patient refusal, transplantation, etc.
18 months, developed a thrombosis (study endpoint), or discon-
tinued from the study due to an adverse event. Thirty-four
patients were discontinued from the study due to adverse
events.
Outcome in Type I and Type II patients are shown in Table 2.
Analyzing crude thrombosis rates for 84 Type I patients sug-
gested a positive effect of dipyridamole and a negative effect of
aspirin. Those treated with dipyridamole had half the rate of
thrombosis of those not treated with dipyridamole (20% vs.
41%, P = 0.062), whereas patients treated with aspirin had
higher rates than those treated without aspirin (36% vs. 24%,
P 0.34). The lowest rate of thrombosis (17%) occurred in
patients treated with dipyridamole alone while the highest rate
(50%) occurred in patients treated with aspirin alone. Throm-
bosis in patients receiving dipyridamole and aspirin combina-
tion was 23% while that in the placebo group was 32%.
Using actuarial analysis with Cox proportional hazards model
in Type I patients, the beneficial effect of dipyridamole was
again evident. Thus, at the end of the 18 month follow-up, the
cumulative rates of thrombosis were: 21 9% on dipyridamole
Fig. 1. Cumulative proportion of ePTFE
grafts without thrombosis in Type I patients.
The relative risk of thrombosis with
dipyridamole was 0.35 (P = 0.02) and relative
risk of thrombosis with aspirin was 1.99 (P =
0.18). The P values have been multiplied by 20 60 120 180 240 300 360 420 480 540 600 in order to adjust for subgroup analysis.
Symbols are: (U) dipyridamole; (G) aspirin;
Time, days from surgery to thrombosis (A) dipyridamole + aspirin; () placebo.
Treatment groups
Dipyridamole
Dipyridamole Aspirin + aspirin Placebo Total
Total treated 29 26 28 24 107
1. Cardiaca 2 2 3 2 9
2. GastrointestinaV' 5 3 5 2 15
3. Other
Headache 3 0 4 1 8
Nausea 2 2 3 4 11
Vomiting 2 1 3 3 9
Miscellaneous 3 2 2 1 8
a Six of the 9 patients who experienced cardiac adverse events had prior history of cardiac ischemia before participation in the study.b Five of the 15 patients who experienced GI adverse events had remote history of GI hemorrhage or peptic ulceration before participation in
the study.
alone, 25 11% on dipyridamole and aspirin combination, 42
13% on placebo, and 80 12% on aspirin alone (Fig. 1). The
relative risk of thrombosis with dipyridamole was estimated to
be 0.35 (P = 0.02, after adjustment for subgroup analysis) with
95% confidence limits of 0.15 and 0.80. By contrast, the relative
risk with aspirin was 1.99 with 95% confidence limits of 0.88 and
4.48. However, this effect was not statistically significant (P =
0.18). No evidence of interaction between dipyridamole and
aspirin was found (P = 0.33).
Type II patients had high thrombosis rates regardless of the
treatment group. Overall there was 78% thrombosis in Type II
patients and there were no statistical differences between study
groups (Table 2). The number of patients per treatment group
was too few for actuarial analysis.
Adverse effects
Adverse experiences determined to be either probably or
possibly related to the investigational drug(s) were reported by
20 (69%) patients treated with dipyridamole alone, 15 (58%)
patients treated with aspirin alone, 18 (62%) patients treated
with both dipyridamole and aspirin, and 16 (67%) patients who
received placebo. These were not statistically significantly
different from each other. The most common serious adverse
events were angina pectoris and gastrointestinal (01) bleeding.
Table 3 lists some of the adverse events reported during the
study period. Seven deaths occurred during the study, one each
in dipyridamole alone and aspirin alone groups, two in dipyri-
damole and aspirin combination group, and three in the placebo
group.
Discussion
Several studies have estimated the probability of thrombosis
of PTFE grafts at one year to range from 49 to 72% [6, 7, 151. In
the Canadian Hemodialysis Morbidity Study [161, a multicenter
prospective cohort study, the likelihood of graft thrombosis at
one year was 39.9%. This is similar to the overall crude
thrombosis rate observed in our study (40%). Conservative
estimates of the cost of treating access-related complications
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have varied from 150 to 500 million dollars per year in the US
[1, 2]. These estimates do not include the costs of out-patient
treatments provided. Because of the higher rates of thrombosis
and infection, the majority of these costs are related to PTFE
grafts. In addition, the Canadian hemodialysis morbidity study
documented a 2.49-fold increase in the probability of hospital-
ization for any cause in patients with synthetic vascular access
grafts compared to those with autologous vein fistula [161.
The most common mode of synthetic vascular access failure
is via stenosis of the graft-venous anastomosis that results from
neointimal hyperplasia of the smooth muscle cells and extracel-
lular matrix [17, 18]. Such a stenosis has been shown to be
present in at least 67% of all access failures [8]. A recent review
[19] discusses the current understanding of the pathogenesis of
neointimal hyperplasia. The mechanism that has received most
of the experimental support in animal models of graft patency is
platelet activation, which can result from the interaction of
platelets with foreign (graft) surfaces, as well as from turbulent
flow [20, 211. Once activated, platelets release platelet-derived
growth factor (PDGF), thromboxane A2 and other substances
that may promote further platelet aggregation as well as have
direct vascular effects. In addition, shear-induced intimal injury
and repair also participate in the proliferative response by the
smooth muscle cell. Finally, dialyzer membranes also vary in
thrombogenicity [22], and may participate in platelet activation
[23].
The results of this prospective, double-blind, placebo-con-
trolled study suggest a potentially important role for dipyridam-
ole in preventing graft thrombosis in patients with a new
arteriovenous ePTFE graft. Thus, patients on dipyridamole
alone had a graft patency rate of 79% at the end of the study, the
best patency rate of all study groups, whereas the group on
dipyridamole and aspirin combination had the second best
patency rate (75%). However, this beneficial effect appears to
be specific for Type I (new ePTFE graft) patients only. In
patients enrolled in the study after graft thrombosis and a
thrombectomy and/or revision (Type II patients) there was no
benefit from the use of dipyridamole.
Dipyridamole has been shown to have multiple, possibly
synergistic, mechanisms [241 that may explain these results.
Dipyndamole inhibits cAMP-phosphodiesterase [25] causing a
rise in intracellular cAMP and free calcium in platelets, thus
inhibiting platelet activation. Dipyridamole also potentiates the
inhibitory effects of adenosine on platelet function by blocking
reuptake by vascular and blood cells [24]. It potentiates the
anti-aggregatory effects of prostacyclin [26] and enhances pros-
tacyclin biosynthesis [27]. Dipyridamole has been shown to
increase 13-hydroxyoctadecadienoic acid (13-HODE) produc-
tion by endothelium making the vessel wall less "adhesive" to
platelets [28]. These mechanisms lead to inhibition of platelet
adhesion to subendothelium and prosthetic materials [29],
platelet release reaction and platelet aggregation [30]. Finally,
dipyridamole has been shown to decrease serum PDGF level,
and selectively decrease the level of fibroblast mitogenic activ-
ity (a biological marker of PDGF) whereas aspirin does not
possess such effects [31].
In addition to these in vitro defined mechanisms, the results
of several large clinical trials support the advantages of adding
dipyndamole to aspirin. In the "Group Espanol para el
Seguimiento del Injerto Coronario" (GESIC) study [32], only
the outcome in the aspirin/dipyridamole combination group was
significantly better than placebo, whereas the group treated
with aspirin alone was not. In a meta-analysis of 25 trials of
anti-platelet treatment including 29,000 patients [33], the Anti-
platelet Trialists' Collaboration found that the combination of
aspirin and dipyridamole decreased new vascular events 31%
compared to only 24% with aspirin alone. More recently Weber
et al [28] demonstrated that in rabbits treated with dipyridam-
ole, vessel wall thrombogenicity was decreased by half whereas
those treated with salicylate had a twofold increase, a highly
significant difference. They attributed the beneficial effect of
dipyridamole to the increase in 13-HODE synthesis.
The explanation for the lack of benefit from dipyridamole in
Type II patients is conjectural. The presence or extent of
proximal venous stenoses was not systematically examined in
this study. Schwab and others [34—36] have shown in several
studies that the presence of these stenoses is strongly associ-
ated with subsequent thrombosis of the graft, while their
correction by surgery or angioplasty significantly improves the
prognosis for graft patency. Thus, the presence of such proxi-
mal venous stenoses may have contributed to the lack of
pharmacological benefit from any treatment in Type II patients.
Indeed, graft survival rates were extremely poor in all groups of
Type II patients in this study and the overall rate of re-
thrombosis was 78% (18/23 patients).
An unexpected result of this study was the fact that aspirin
therapy was associated with an increase in the development of
fistula thrombosis in patients receiving new ePTFE grafts
compared to dipyridamole and placebo. Although we did not
study the mechanism(s) of such an increase it is possible that
cyclooxygenase inhibition by aspirin may shift platelet arachi-
donic acid metabolism in the direction of l2-L-hydroxy-
5,8,10, 14-eicosatetraenoic acid (1 2-HETE) production via
platelet-derived 12-lipoxygenase. 12-HETE has been shown to
mediate the PDGF-induced chemoattraction of vascular smooth
muscle cells [37, 38]. Thus, platelet cyclooxygenase inhibition
may paradoxically enhance the development of neointimal
hyperplasia and increase rate of graft thrombosis. Recent
studies also suggest that aspirin does not inhibit the interaction
of platelets with monocytes and polymorphonuclear cells, its
expression of P-selectin, nor its ability to release a-granules
which contain PDGF [39]. It is also possible that the dose of
aspirin used in this study blocked the production of prostacyclin
by the endothelial cells, thus abrogating the anti-aggregatory
effects of prostacyclin [40]. Finally, Weber et al have demon-
strated that salicylate was associated with decreased 13-HODE
synthesis and increased platelet adhesion whereas dipyridamole
had opposite effects [28]. Further research will be needed to
confirm these observations and to define the relative mecha-
nisms in uremic patients. Nevertheless, these results along with
others [41—431 suggest that aspirin can have effects in uremic
patients different from normal controls.
Despite the apparent promise of dipyndamole in preventing
graft thrombosis in newly placed ePTFE grafts reported in this
study, it is important to point out the limitations of such a
conclusion. First, the efficacy of dipyndamole was seen at a
time when EPO was not routinely used. Additionally, this study
was conducted in a single center. Thus, further studies to
confirm the potentially beneficial effects of dipyndamole and
adverse effects of aspirin will need to be undertaken. Finally,
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although there were no statistically significant differences in the
incidence of side effects among different treatment regimens
including the group on placebo, all were relatively high. It is
possible that lower doses of the drugs, particularly dipyridam-
ole, may be equally effective, but with fewer side effects.
More importantly, this study points out the magnitude of the
problem of access failure and the urgent need for more innova-
tive methods to reduce this high incidence. Newer strategies
like hepann bonding to graft material [44], use of low molecular
weight heparin [45] and materials with decreased thromboge-
nicity [44, 46], as well as endothelial seeding of the graft
material [47] may also be helpful but, obviously, need further
investigation. Finally, other pharmacologic interventions to
prevent HD vascular access thrombosis as has been recently
reviewed should be considered [48].
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